Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Neurofibromatosis Type 1 Market: By Drug type, By Disease Type, By Treatment Type, By Distribution Channel, and Geography
Neurofibromatosis Type 1 Market size was valued at US$ 8,356.3 million in 2023 and is expected to grow at an 9.3% CAGR from 2024 to 2030. Neurofibromatosis Type 1 is a complex genetic disorder characterized by the development of tumors along nerves in the skin, brain, and other parts of the body. This condition affects approximately 1 in 3,000 to 4,000 individuals worldwide, making it one of the most common inherited neurological disorders. One of the primary drivers is the increasing prevalence of neurofibromatosis type 1. This growing patient population is fueling demand for improved diagnostic tools and treatment options. Advancements in diagnostic techniques have also contributed to neurofibromatosis type 1 market growth. The introduction of next-generation sequencing and other molecular diagnostic methods has enhanced the accuracy and speed of neurofibromatosis type 1 diagnosis. For instance, a 2023 study reported that advanced genetic testing techniques could identify neurofibromatosis type 1 mutations in over 95% of cases, compared to about 80% with traditional methods. Growing awareness among healthcare professionals and the general public is another crucial factor. Patient advocacy groups and initiatives like the Children's Tumor Foundation's "Shine a Light on NF" campaign have significantly increased visibility and understanding of the condition.
This has led to earlier diagnoses and increased research funding for neurofibromatosis type 1. The neurofibromatosis type 1 market presents several opportunities, particularly in the development of targeted therapies and personalized medicine approaches. The approval of selumetinib in 2020 for pediatric neurofibromatosis type 1 patients with symptomatic, inoperable plexiform neurofibromas marked a significant milestone. This has paved the way for increased investment in similar targeted therapies, with over 30 clinical trials for neurofibromatosis type 1 treatment registered as of 2024. However, the neurofibromatosis type 1 market faces certain restraints, including the complexity of the disease and limited treatment options for all manifestations of neurofibromatosis type 1. The heterogeneity of symptoms and the unpredictable nature of tumor growth pose challenges for developing universally effective treatments. Current trends in the neurofibromatosis type 1 market include a focus on gene therapy research, with several preclinical studies showing promising results. The use of artificial intelligence in diagnosis and treatment planning is also gaining traction. A recent pilot study demonstrated that AI algorithms could detect neurofibromatosis type 1-associated tumors with 92% accuracy, potentially speeding up diagnosis and monitoring. Collaborative efforts between pharmaceutical companies and research institutions have accelerated drug development.
Study Period
2024-2030Base Year
2023CAGR
9.3%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The Neurofibromatosis Type 1 market is significantly driven by increasing prevalence and advancements in diagnostic techniques. Recent epidemiological studies suggest neurofibromatosis type 1 may affect up to 1 in 2,000 individuals worldwide, higher than previous estimates. This rise in prevalence is partly due to improved detection capabilities and increased awareness among healthcare professionals, leading to more accurate and early diagnoses. The genetic nature of neurofibromatosis type 1, with a 50% inheritance rate, also contributes to its growing prevalence. Simultaneously, diagnostic technologies have undergone remarkable advancements. Next-generation sequencing techniques have improved genetic testing accuracy, now detecting neurofibromatosis type 1 mutations in over 95% of cases compared to 80% with traditional methods. Molecular imaging, particularly whole-body MRI, has enhanced the detection and monitoring of internal neurofibromas. The integration of artificial intelligence in image analysis shows promise in identifying neurofibromatosis type 1-associated tumors with high accuracy, potentially expediting diagnosis and monitoring processes.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 8,356.3 million |
Market CAGR |
9.3% |
By Drug Type |
|
By Disease type |
|
By Treatment |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
Neurofibromatosis Type 1 Market was valued at US$ 8,356.3 million in 2023 and is expected to grow at an 9.3% CAGR from 2024 to 2030.
AstraZeneca plc, Novartis AG, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Johnson & Johnson, and F. Hoffmann-La Roche Ltd. are some of the major players operating in the neurofibromatosis type 1 market.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the neurofibromatosis type 1 market.
Key challenges include the variable expression of the disease, the complexity of the neurofibromatosis type 1 gene, and the need for long-term studies to assess treatment efficacy and safety.
Yes, in 2020, the FDA approved selumetinib for the treatment of pediatric patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
1.Executive Summary |
2.Global Neurofibromatosis Type 1 Market Introduction |
2.1.Global Neurofibromatosis Type 1 Market - Taxonomy |
2.2.Global Neurofibromatosis Type 1 Market - Definitions |
2.2.1. Drug Type |
2.2.2.Disease type |
2.2.3.Treatment |
2.2.4.Distribution Channel |
2.2.5.Region |
3.Global Neurofibromatosis Type 1 Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Neurofibromatosis Type 1 Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Neurofibromatosis Type 1 Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Lamotrigine |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Selumetinib |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Others |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Neurofibromatosis Type 1 Market By Disease type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Plexiform Neurofibromas |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Cutaneous Neurofibromas |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Optic Gliomas |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Neurofibromatosis Type 1 Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Medication |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Surgery |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Radiation Therapy |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Neurofibromatosis Type 1 Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9.Global Neurofibromatosis Type 1 Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Lamotrigine |
10.1.2.Selumetinib |
10.1.3.Others |
10.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Plexiform Neurofibromas |
10.2.2.Cutaneous Neurofibromas |
10.2.3.Optic Gliomas |
10.2.4.Others |
10.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Medication |
10.3.2.Surgery |
10.3.3.Radiation Therapy |
10.3.4.Others |
10.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital Pharmacies |
10.4.2.Retail Pharmacies |
10.4.3.Online Pharmacies |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Lamotrigine |
11.1.2.Selumetinib |
11.1.3.Others |
11.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Plexiform Neurofibromas |
11.2.2.Cutaneous Neurofibromas |
11.2.3.Optic Gliomas |
11.2.4.Others |
11.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Medication |
11.3.2.Surgery |
11.3.3.Radiation Therapy |
11.3.4.Others |
11.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital Pharmacies |
11.4.2.Retail Pharmacies |
11.4.3.Online Pharmacies |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Lamotrigine |
12.1.2.Selumetinib |
12.1.3.Others |
12.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Plexiform Neurofibromas |
12.2.2.Cutaneous Neurofibromas |
12.2.3.Optic Gliomas |
12.2.4.Others |
12.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Medication |
12.3.2.Surgery |
12.3.3.Radiation Therapy |
12.3.4.Others |
12.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital Pharmacies |
12.4.2.Retail Pharmacies |
12.4.3.Online Pharmacies |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Lamotrigine |
13.1.2.Selumetinib |
13.1.3.Others |
13.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Plexiform Neurofibromas |
13.2.2.Cutaneous Neurofibromas |
13.2.3.Optic Gliomas |
13.2.4.Others |
13.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Medication |
13.3.2.Surgery |
13.3.3.Radiation Therapy |
13.3.4.Others |
13.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital Pharmacies |
13.4.2.Retail Pharmacies |
13.4.3.Online Pharmacies |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Neurofibromatosis Type 1 Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Lamotrigine |
14.1.2.Selumetinib |
14.1.3.Others |
14.2. Disease type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Plexiform Neurofibromas |
14.2.2.Cutaneous Neurofibromas |
14.2.3.Optic Gliomas |
14.2.4.Others |
14.3. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Medication |
14.3.2.Surgery |
14.3.3.Radiation Therapy |
14.3.4.Others |
14.4. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital Pharmacies |
14.4.2.Retail Pharmacies |
14.4.3.Online Pharmacies |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.AstraZeneca plc |
15.2.2.Novartis AG |
15.2.3.Merck & Co., Inc. |
15.2.4.Pfizer Inc. |
15.2.5.Sanofi S.A. |
15.2.6.Johnson & Johnson |
15.2.7.Hoffmann-La Roche Ltd. |
15.2.8.Takeda Pharmaceutical Company Limited |
15.2.9.Eli Lilly and Company |
15.2.10.GlaxoSmithKline plc |
15.2.11.Bristol-Myers Squibb Company |
15.2.12.Bayer AG |
15.2.13.Boehringer Ingelheim International GmbH |
15.2.14.Gilead Sciences, Inc. |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players